乳腺癌患者基质金属蛋白酶抑制因子－1和人类表皮生长因子受体－2表达的临床意义研究

摘要

Objective To investigate the clinical significance of tissue inhibitors of metalloproteinase-1 ( TIMP-1 ) and human epider-mal growth factor receptor 2 ( HER-2 ) expression in breast cancer patients. Methods 98 breast cancer patients from January 2006 to December 2007 were collected and followed-up for 5 years, then the relations between TIMP-1, HER-2 and clinical pathological features of breast cancer patients were analyzed, and the overall survival ( OS ) was applied to assess the patients' prognosis. Results The rate of TIMP-1 positive expression was 57. 14%, and HER-2 was 42. 86%. The TMP-1 and HER-2 expressions and patient age, tumor size, clinical stage and histological type were irrelevant ( P ﹥ 0. 05 );TIMP-1 expression and lymph node metastasis, histologi-cal grade were relevant ( P ﹤ 0. 05 );HER-2 and ER, PR status information were relevant ( P ﹤ 0. 05 ) , the 5-year survival rate of pa-tients with TIMP-1 expression ( 61. 79%) was less than that of patients with no TIMP-1 expression ( 66. 64%) , and there was no sta-tistical difference ( P ﹥ 0. 05 );the 5-year survival rate of patients HER-2 expression ( 56. 43%) was significantly lower than that of pa-tients with the negative HER-2 expression ( 64. 32%) , and there was statistical difference ( P ﹤ 0. 05 ) . Conclusion TIMP-1 expression is related to lymphatic metastasis and tissue differentiation but it may be not an independent predictor of poor prognosis. The 5-year survival rate of HER-2 positive expression is significantly lower, which could be used as an adverse prognostic indicator.%目的：观察基质金属蛋白酶抑制因子－1（TIMP－1）和人类表皮生长因子受体－2（HER－2）在乳腺癌患者中的表达及其临床意义。方法收集2007年1月至2008年12月收治的乳腺癌患者98例，所有病例均随访5年，分析TIMP－1和HER－2在乳腺癌中的表达与不同临床病理特征的关系，应用总生存时间（OS）评估患者预后情况。结果全组肿瘤组织TIMP－1阳性表达率为57.14%，HER－2为42.86%，二者的表达与患者年龄、肿瘤大小、临床分期和病理类型均无关（ P﹥0.05）；TIMP－1的表达与淋巴结转移、组织学分级有关（ P﹤0.05）；HER－2与雌激素受体( ER )、孕激素受体( PR )状态有关（ P﹤0.05）。TIMP－1表达者5年生存率为61.79%，低于TIMP－1未表达者的66.64%，差异无统计学意义（ P﹥0.05）；HER－2表达者5年生存率为56.43%明显低于未表达者的64.32%（ P﹤0.05）。结论 TIMP－1表达者可能与肿瘤淋巴转移、组织分化有关，但不能作为不良预后的独立指标；HER－2阳性表达者5年生存率明显较低，可作为不良预后指标。